›› 2015, Vol. 42 ›› Issue (2): 401-407.doi: 10.16431/j.cnki.1671-7236.2015.02.026

Previous Articles     Next Articles

Study on Ivermectin Nanoemulsion for Transdermal Drug Delivery

DING Dan1, SHENG Xiao-li2, LIANG Kong-xian1, XU Qi3, LIU Wei1,2,3   

  1. 1. College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China;
    2. National Engineering Research Center for Nanomedicine, Huazhong University of Science and Technology, Wuhan 430074, China;
    3. Wuhan Best-carrier Nano Science and Technology Co., Ltd., Wuhan 430074, China
  • Received:2014-08-27 Online:2015-02-20 Published:2015-02-13

Abstract: The aim of the study was to prepare ivermectin nanoemulsion for transdermal drug delivery.The physicochemical property,stability,in vitro drug release and transdermal property were evaluated.The optimal drug loading with good stability and larger nanoemulsion region was investigated by ternary phase diagram.The response surface methodology was used for selecting the optimal prescription.The average diameter,zeta potential,morphology,pH and viscosity were also investigated.In vitro drug release and transdermal property of ivermectin nanoemulsion and market ivermectin skin varnish were compared by dialysis bags and Franz diffusion cells.The nanoemulsion region was largest and most stable when the drug loading was 2.00%.The optimal prescription was Cremophor EL-35 :Transcutol HP :ethyl oleate :ivermectin :H2O=26: 12: 7: 2: 53 and its average diameter was 18 nm.The ivermection nanoemulsion was stable when it was stored in 4 ℃ refrigerator and room temperature for 1 year.The cumulative permeation and retention of ivermectin nanoemulsion in 24 h were 3.24 and 2.05 times over the commercially available varnish,respectively.These results indicated that the ivermectin nanoemulsion had the advantages of simple preparation process,excellent stability and transdermal property,and had good application prospects.

Key words: ivermectin; nanoemulsion; ternary phase diagram; response surface methodology; in vitro drug release; transdermal property

CLC Number: